CRISPR Therapeutics AG (CRSP)
52.92
+1.20
(+2.32%)
USD |
NASDAQ |
Sep 14, 15:58
CRISPR Therapeutics Enterprise Value : 3.418B for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 3.418B |
| September 10, 2026 | 3.471B |
| September 09, 2026 | 3.586B |
| September 08, 2026 | 3.714B |
| September 04, 2026 | 3.812B |
| September 03, 2026 | 3.879B |
| September 02, 2026 | 3.921B |
| September 01, 2026 | 3.911B |
| August 31, 2026 | 3.927B |
| August 28, 2026 | 3.998B |
| August 27, 2026 | 4.158B |
| August 26, 2026 | 4.144B |
| August 25, 2026 | 4.306B |
| August 24, 2026 | 3.936B |
| August 21, 2026 | 4.170B |
| August 20, 2026 | 4.037B |
| August 19, 2026 | 4.200B |
| August 18, 2026 | 3.539B |
| August 17, 2026 | 3.666B |
| August 14, 2026 | 3.595B |
| August 13, 2026 | 3.638B |
| August 12, 2026 | 3.638B |
| August 11, 2026 | 3.645B |
| August 10, 2026 | 3.591B |
| August 07, 2026 | 3.592B |
| Date | Value |
|---|---|
| August 06, 2026 | 3.411B |
| August 05, 2026 | 3.489B |
| August 04, 2026 | 3.549B |
| August 03, 2026 | 3.211B |
| July 31, 2026 | 3.058B |
| July 30, 2026 | 3.101B |
| July 29, 2026 | 3.024B |
| July 28, 2026 | 3.015B |
| July 27, 2026 | 2.936B |
| July 24, 2026 | 2.918B |
| July 23, 2026 | 3.013B |
| July 22, 2026 | 2.985B |
| July 21, 2026 | 3.073B |
| July 20, 2026 | 2.961B |
| July 17, 2026 | 3.037B |
| July 16, 2026 | 3.114B |
| July 15, 2026 | 3.384B |
| July 14, 2026 | 3.297B |
| July 13, 2026 | 3.313B |
| July 10, 2026 | 3.576B |
| July 09, 2026 | 3.865B |
| July 08, 2026 | 4.141B |
| July 07, 2026 | 4.293B |
| July 06, 2026 | 4.401B |
| July 02, 2026 | 4.226B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Vertex Pharmaceuticals, Inc. | 124.70B |
| Basilea Pharmaceutica AG | -- |
| Santhera Pharmaceuticals Holding AG | -- |
| BeOne Medicines Ltd. | 32.89B |
| AC Immune SA | 163.10M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -91.15M |
| Revenue (Quarterly) | 10.18M |
| Total Expenses (Quarterly) | 101.34M |
| EPS Diluted (Quarterly) | -0.9445 |
| Gross Profit Margin (Quarterly) | -337.8% |
| Profit Margin (Quarterly) | -895.3% |
| Earnings Yield | -9.00% |
| Normalized Earnings Yield | -9.039 |